Replies to post #188520 on Biotech Values

[pollyvonwog]

Probably the same for GILD's next gen as well, no?

Seems like MRK is going to have a heck of a time breaking into the market.

[caravon]

US payer contracts for V-Pak anticipate switch to 2nd-generation HCV regimen (ABT-493/ABT-530) when approved.

This is nothing more than a cheap propaganda by Abbv since nobody has any idea about 2nd-generation HCV regimens efficacy, side-effects, treatment duration, cost or even who these players will be.